Page 2 - Net Research News Today

Significant clinical progress in the treatment of stroke with glenzocimab: Positive results from the ACTIMIS phase 1b/2a study Patent granted to protect glenzocimab in thrombotic

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Successful IPO on Euronext Growth in Paris Cash position of €11.3 million at 31 December 2021 Promising clinical results with the continuing development of glenzocimab for use in stroke Regulatory

•Reaffirms 2021 Full Year Forecast for Revenues and Profit GAITHERSBURG, Md., July 29, 2021-Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the second quarter ended June 30, 2021. Our second quarter performance demonstrates the strength of our strategy and diversified business model, said Robert G. Kramer, president and chief executive officer of Emergent BioSolutions. Through continued investment and innovation, we will play an important role in ...

DFnet and ClinConsent Join Forces to Meet Growing Demand for Patient-Centric eConsent Solutions Share Article SEATTLE (PRWEB) April 13, 2021 DF/Net Research, Inc. (DFnet), a trusted leader in clinical data management solutions, today announced its partnership with ClinConsent, LLC. ClinConsent is a leading electronic informed consent (eIC) software provider. This partnership will further extend DFnets suite of clinical data manage...

(0.28) Summary of operational events (more details are provided in the corresponding press releases available on Biophytiss website: www.biophytis.com) Launch of the Phase 2-3 COVA study in patients with severe respiratory manifestation of COVID-19 In May 2020, Biophytis received approval from the Belgian Federal Agency for Medicines and Health Products (FAMHP), to proceed with its clinical development program COVA, a two-part study assessing Sarconeos (BIO101) in patients aged 45 and older, ...